News Releases

Date Title View
Toggle Summary Aerie Pharmaceuticals Announces U.S. Launch of Rocklatan® and Increase in Rhopressa® Medicare Part D Coverage to Approximately 75% of Lives
DURHAM, N.C. --(BUSINESS WIRE)--May 1, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce First Quarter 2019 Financial Results and Host Conference Call on Tuesday, May 7, 2019
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 30, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-13503 Sustained Release Implant
First-In-Human Clinical Study Will be Initiated Later in Second Quarter 2019 DURHAM, N.C. --(BUSINESS WIRE)--Apr. 25, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 2, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Gianluca Corbinelli as Chief Commercial Officer - Europe
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 1, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Four Appointments
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 25, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Designed to Support Requirements for Future Regulatory Filing
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 21, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 18, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Full-Year 2019 Net Revenue and Net Cash Burn Guidance
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 12, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Announces U.S. FDA Approval of Rocklatan™ (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension
– First and Only Once-Daily , Fixed-Dose Combination of a Prostaglandin Analog and a Rho Kinase (ROCK) Inhibitor – – Rocklatan™ Demonstrated Statistical Superiority over Widely-Prescribed First-Line Agent Latanoprost – DURHAM, N.C. --(BUSINESS WIRE)--Mar. 12, 2019-- Aerie Pharmaceuticals, Inc.
View HTML
TOP